Wuestefeld, Anika
Pichet Binette, Alexa
van Westen, Danielle
Strandberg, Olof
Stomrud, Erik
Mattsson-Carlgren, Niklas
Janelidze, Shorena
Smith, Ruben
Palmqvist, Sebastian
Baumeister, Hannah
Berron, David
Yushkevich, Paul A.
Hansson, Oskar
Spotorno, Nicola
Wisse, Laura E.M.
Funding for this research was provided by:
Lund University
Article History
Received: 16 May 2024
Accepted: 4 September 2024
First Online: 16 September 2024
Declarations
:
: The study was approved by the Regionala Etiksprövningsnämnden i Lund (regional ethical review board in Lund), Sweden, and all study participants provided written informed consent in accordance with the Declaration of Helsinki.
: Not applicable.
: A.W., A.P.B., H.B., E.S., O.S., D.W., N.M.-C, N.S., P.A.Y., and L.E.M.W. have nothing to declare. D.B. is co-founder of neotiv GmbH. R.S. has received a speaker fee from Roche. S.P. has acquired research support (for the institution) from ki elements / ADDF and Avid. In the past 2 years, he has received consultancy/speaker fees from Bioartic, Biogen, Esai, Lilly, and Roche. O.H. has acquired research support (for the institution) from AVID Radiopharmaceuticals, Biogen, C2N Diagnostics, Eli Lilly, Eisai, Fujirebio, GE Healthcare, and Roche. In the past 2 years, he has received consultancy/speaker fees from AC Immune, Alzpath, BioArctic, Biogen, Bristol Meyer Squibb, Cerveau, Eisai, Eli Lilly, Fujirebio, Merck, Novartis, Novo Nordisk, Roche, Sanofi and Siemens.